Regenacy Pharmaceuticals

Recent Finacing

Series B

Recent Raise

$9.3M

Regenacy Pharmaceuticals develops ricolinostat, an oral selective HDAC6 inhibitor for diabetic, chemotherapy‑induced, and genetic peripheral neuropathies, and maintains HDAC1/2 programs for blood and neurological disorders.

Founded 2016

Massachusetts, United States

1-10

Private

regenacy.com

Highlights

Focus Areas

Biotechnology

Health Care

Medical

Service Industry

Therapeutics

Recent Investors

Financials

$39.3M

Total Raised

2

Funding rounds

6

Investors

Team

Upgrade to view the team

See the team members at Regenacy Pharmaceuticals.